


# Apixaban, Anticoagulation, & Atrial Fibrillation

Kristin Heck Coverly  
Creighton University SPAHP  
Pharm D Candidate  
March 8, 2013

## Introduction

- Warfarin & Atrial Fibrillation
- New Players
  - Apixaban
  - Dabigatran
  - Rivaroxaban



## Apixaban Basics<sup>1,2,3</sup>

- MOA
- Side Effects & Surgery
- Dosing & Converting
- Drug interactions
- Warnings & Contraindications
- Monitoring
- Reversal Agents
- PK

## Dabigatran & Rivaroxaban<sup>1,2,4,5</sup>

- Table 1—Comparison Chart
- Notable Differences



## ARISTOTLE<sup>6,7</sup>

- Study Basics
- Study Outcomes
- Results: Table 2
- Impression:
  - Apixaban is SUPERIOR to Warfarin



## RE-LY<sup>7,8</sup>

- Study Basics
- Study Outcomes
- Results: Table 3
- Impressions:
  - Dabigatran is non-inferior (primary)
  - Dabigatran 150 mg is superior (primary)
  - Dabigatran 110 mg is superior (major bleeding)

## ROCKET AF<sup>7,9</sup>

- Study Basics
- Study Outcomes
- Results: Table 4
- Impression:
  - Rivaroxaban is NON-INFERIOR to Warfarin

## Limitations<sup>5,7</sup>

- Dosing
- Cost
- Drug Interactions
- Renal & Liver Impairment
- Reversal Agents




## Indirect Comparison<sup>6,8,9,10</sup>

- Warfarin Compliance
- CHADS<sub>2</sub> Scores
- Study Design
- Primary Safety Outcome

## Final Thoughts

- Favorable Study Results
- Direct Comparison?
- Clinical Judgment



## References

- 1. Lexi-Comp Website. "Apixaban." [http://online.lexi.com.cuhsj.creighton.edu/lco/action/doc/retrieve/docid/patch\\_f/3804162](http://online.lexi.com.cuhsj.creighton.edu/lco/action/doc/retrieve/docid/patch_f/3804162). Accessed February 20, 2013.
- 2. Clinical Pharmacology Website. "Apixaban." <http://www.clinicalpharmacology-ip.com.cuhsj.creighton.edu/Forms/drugoptions.aspx?cpnum=3795&n=Apixaban&i=0>. Accessed February 22, 2013.
- 3. Nutescu E. Apixaban: A novel oral inhibitor of factor Xa. *Am J Health-Syst Pharm.* 2012; 69: 1113-1126.
- 4. Lexi-Comp Website. "Dabigatran." [http://online.lexi.com.cuhsj.creighton.edu/lco/action/doc/retrieve/docid/patch\\_f/1200582#f\\_pharmacology-and-pharmacokinetics](http://online.lexi.com.cuhsj.creighton.edu/lco/action/doc/retrieve/docid/patch_f/1200582#f_pharmacology-and-pharmacokinetics). Accessed February 22, 2013.
- 5. Lexi-Comp Website. "Xarelto." [http://online.lexi.com.cuhsj.creighton.edu/lco/action/doc/retrieve/docid/patch\\_f/1275239](http://online.lexi.com.cuhsj.creighton.edu/lco/action/doc/retrieve/docid/patch_f/1275239). Accessed February 22, 2013.
- 6. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. *NEJM.* 2011; 365: 981-992.
- 7. Hollands JM, Gowan M, Riney JN, et al. Role of New Drugs for Management of Atrial Fibrillation. *The Annals of Pharmacotherapy.* 2012; 46:1656-1670.
- 8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. *NEJM.* 2009; 361: 1139-1151.
- 9. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. *NEJM.* 2011; 365: 883-891.
- 10. Xu B, Whitbourn R. Novel Anticoagulants for Non-valvular Atrial Fibrillation. *Heart, Lung, and Circulation.* 2012; 21: 463-467.

## Questions?

